[CAS NO. 171746-21-7] AGN 193109
PRODUCTS SPECIFICATIONS [171746-21-7]
DESCRIPTION [171746-21-7]
Overview
| MDL | MFCD00943817 |
|---|---|
| Molecular Weight | 392.49 |
| Molecular Formula | C28H24O2 |
| SMILES | O=C(O)C1=CC=C(C#CC2=CC=C3C(C)(C)CC=C(C4=CC=C(C)C=C4)C3=C2)C=C1 |
2 Publications Citing Use of MCE
Summary
AGN 193109 (GMP) is AGN 193109 (HY-U00449) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AGN 193109 is a specific and highly effective retinoic acid receptor ( RAR ) antagonist [1] [2] .
In Vitro
AGN 193109 (0.1 and 1 μmol/L; 3 w) dose-dependently increases vascular smooth muscle cells (VSMCs) mineralization
[1]
.
AGN 193109 (100 nM; 10 d) induces human pluripotent stem cells (hPSCs) differentiate into olfactory placode cells and neurons
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Rogers MA, et al. Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects. Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):656-669.
- [2] Bricker RL, et al. A Molecular Analysis of Neural Olfactory Placode Differentiation in Human Pluripotent Stem Cells. Stem Cells Dev. 2022 Sep;31(17-18):507-520.
Synonyms